weight loss pill
Search documents
Changing Stance On Ukrainian Territory
Seeking Alpha· 2025-09-24 11:29
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Spotify.Getty Images Good morning! Catch up on the latest in trending news:Slice of the pie: Lithium Americas (LAC) continues to rally this morning, as the Trump administration is said to be seeking an equity stake in the company. The news comes as the government reevaluates its $2.3B loan for Thacker Pass, the largest known lithium deposit in the U.S. Bright outlook: Micron Technology (MU) e ...
Investor Optimism Builds With IPO Strength, Fed Cuts, And Gold Surge
Forbes· 2025-09-22 13:10
Market Performance - All four major indices posted solid gains, with the Nasdaq Composite leading at almost 2.25% increase [2] - Small cap stocks also performed well, as the Russell 2000 added just under 2.2% [2] - The S&P 500 gained nearly 1.25%, while the Dow Jones Industrial Average was up just over 1% [2] Economic Outlook - Markets are anticipating two more rate cuts from the Fed this year, one in October and another in December [3] - The upcoming economic data will be closely scrutinized, particularly the Personal Consumption Expenditures (PCE) Index, which is the Fed's preferred inflation gauge [4][3] IPO Market - The IPO market is showing strength, with many companies being oversubscribed, indicating strong investor interest [5] - There is currently $7.7 trillion in money market funds, suggesting significant capital remains on the sidelines, which could benefit upcoming IPOs [5] Company News - Pfizer is in talks to acquire Metsera for $4.9 billion, focusing on weight loss products [6] - Saks is negotiating to sell a 49% stake to Bergdorf Goodman for $1 billion [6] - Oracle will participate in the consortium purchasing TikTok, responsible for security post-acquisition [6] - Micron Technology is set to report earnings soon, with Costco also scheduled to release earnings later in the week [6] - FactSet estimates earnings growth of nearly 8% for the third quarter, marking the ninth consecutive quarter of growth [6] Commodity Market - Gold has reached a record high, with futures up over 1% to $3747 per ounce, driven by bond market volatility [8] - Investors are turning to gold and silver amid uncertainty in the bond market [8] Emerging Trends - Crypto assets, particularly Bitcoin and Ethereum, experienced significant selloffs but have recovered in premarket trading [9] - Quantum computing and nuclear power stocks have seen massive gains, attributed to growth in Artificial Intelligence [9]
Novo Nordisk aims for FDA approval of weight loss pill
NBC News· 2025-09-18 01:00
Market Trends & Competition - The market for needle-free weight loss options is heating up, with Novo Nordisk's pill form showing similar efficacy to injectable GLP1s [1] - Eli Lilly also shared successful clinical trial results for its weight loss pill, intensifying competition in the oral weight loss medication market [2] - The competition aims for cheaper, more accessible, and better weight loss options with fewer side effects [3] Clinical Trial Results & Efficacy - Novo Nordisk's pill form achieved a 13.6% body weight loss in 64 weeks, with an estimated 16.6% loss if continued [1] - Side effects of the pills are similar to the injections, mainly GI issues and nausea [4] Regulatory Approval & Launch - Novo Nordisk anticipates FDA approval for its daily weight loss pill within a few weeks or months [2] - Novo Nordisk is prepared for a full-scale launch in the US to meet high demand [2] Pricing & Accessibility - Experts believe the pill form will be cheaper to manufacture [2] - The goal is to provide cheaper and more accessible weight loss options [3] Potential Concerns - Doctors are concerned that patients might reduce the frequency of pill intake to minimize discomfort, requiring monitoring [4]
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
Reuters· 2025-09-17 07:43
Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too earl... ...
Eli Lilly advances weight loss pill towards regulatory submissions after successful trial
Proactiveinvestors NA· 2025-08-26 15:01
Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]
Eli Lilly's weight loss pill will likely be the market-leading product, says BofA's Tim Anderson
CNBC Television· 2025-08-26 12:19
Eli Lily shares. Let's have a look at those after that news that we just uh reported that the pharma giant released more data on its obesity pill. Patients with obesity and diabetes lost about 10.5% of their body weight.The data clears the way for Lily to seek regulatory approval. Shares are up 1.7% when they got some data on this a month or so ago or just under a month ago they did fall. Let's get clarity on which bit of the data outweighs the other.Tim Anderson, Bank of America Security senior pharma anal ...
Eli Lilly trials experimental weight loss pill
NBC News· 2025-08-12 20:48
New Drug Development - Eli Lilly's oral GLP-1 drug trial shows potential for a pill form of GLP-1 medication, offering an alternative to injectables [1] - The oral GLP-1 drug is a small molecule absorbed in the stomach, allowing for daily intake instead of weekly injections [3] - Clinical trials indicate that approximately 40% of patients at the highest dose experienced weight loss greater than 15% [5] - The most significant side effect observed with the pill is nausea, similar to other GLP-1 medications [4] - The industry hopes the pill's easier manufacturing and lack of refrigeration needs will lead to significantly lower costs [12] - The industry anticipates potential FDA fast-track approval, possibly leading to market availability sometime next year [15][16] Obesity and GLP-1 - The medical community is shifting away from viewing obesity as a moral failing towards recognizing it as a chronic disease requiring long-term treatment [7][8][9] - GLP-1 medications can help patients overcome the body's natural resistance to weight loss by influencing hormones and reducing the urge to overeat [10][11] - GLP-1 activation may have anti-inflammatory benefits and could potentially improve conditions like autoimmune diseases, psoriasis, and potentially reduce the risk of dementia [13][14] - Over 50% of Americans are considered in the obese range, highlighting the potential impact of accessible treatments on cardiovascular disease and related health issues [12]
Pfizer discontinues development of weight loss pill
Proactiveinvestors NA· 2025-04-14 13:38
Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive adopts technology enthusiastically, utilizing decades of expertise and experience among its content creators [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]